Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States
X Zhang, DC Beachler, E Masters, F Liu… - Journal of Managed …, 2022 - jmcp.org
BACKGROUND: The treatment landscape for advanced nonsmall cell lung cancer (NSCLC)
has evolved from 2015 onward, since the introduction of immune checkpoint inhibitors (ICIs) …
has evolved from 2015 onward, since the introduction of immune checkpoint inhibitors (ICIs) …
Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung …
M Berling, MA Chaudhary, Y Yuan, N Varol… - Journal of medical …, 2022 - Taylor & Francis
Aim We evaluated the cost-effectiveness of nivolumab in combination with ipilimumab
(NIVO+ IPI) versus platinum-doublet chemotherapy (PDC) for the first-line treatment of stage …
(NIVO+ IPI) versus platinum-doublet chemotherapy (PDC) for the first-line treatment of stage …
The value of immunotherapy: Comparison of annual cost per patient receiving immunotherapy versus chemotherapy in patients with non-small cell lung cancer.
MK Vasekar, E Agbese, D Leslie - 2020 - ascopubs.org
e19364 Background: Checkpoint Inhibitors (CPI) has revolutionized cancer treatment but
financial toxicity can be incurred due to high cost. We performed a population-based …
financial toxicity can be incurred due to high cost. We performed a population-based …
Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
X Zeng, X Wan, L Peng, Y Peng, F Ma, Q Liu, C Tan - BMJ open, 2019 - bmjopen.bmj.com
Objectives Evaluating the cost-effectiveness of pembrolizumab plus standard chemotherapy
in the first-line setting for patients with metastatic non-small cell lung cancer (NSCLC) from …
in the first-line setting for patients with metastatic non-small cell lung cancer (NSCLC) from …
[PDF][PDF] Understanding total cost of care in advanced non-small cell lung cancer pre-and postapproval of immuno-oncology therapies
B Korytowsky, J Radtchenko, ED Nwokeji… - Am J Manag …, 2018 - ajmc.s3.amazonaws.com
REPORT reporting patterns of care and costs prior to the approval of targeted and IO
therapies. In addition, many of the published findings are not generalizable, as they …
therapies. In addition, many of the published findings are not generalizable, as they …
Adverse event costs associated with first-line therapy for advanced non–small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint …
BACKGROUND: Immune checkpoint inhibitors, such as pembrolizumab, nivolumab, and
atezolizumab, have demonstrated substantial survival benefits in patients with advanced …
atezolizumab, have demonstrated substantial survival benefits in patients with advanced …
Systematic literature review to identify cost and resource use data in patients with early-stage non-small cell lung cancer (NSCLC)
N Jovanoski, S Abogunrin, D Di Maio, R Belleli… - …, 2023 - Springer
Background Approximately 2 million new cases and 1.76 million deaths occur annually due
to lung cancer, with the main histological subtype being non-small cell lung cancer …
to lung cancer, with the main histological subtype being non-small cell lung cancer …
Healthcare costs in patients with metastatic lung cancer receiving chemotherapy
M Vera-Llonch, D Weycker, A Glass, S Gao… - BMC health services …, 2011 - Springer
Background To characterize healthcare resource utilization and costs in patients with
metastatic lung cancer receiving chemotherapy in the US. Methods Using data from a large …
metastatic lung cancer receiving chemotherapy in the US. Methods Using data from a large …
Disparities in systemic treatment use in advanced-stage non–small cell lung cancer by source of health insurance
FB Maguire, CR Morris, A Parikh-Patel, RD Cress… - … Biomarkers & Prevention, 2019 - AACR
Background: Management of advanced-stage non–small cell lung cancer (NSCLC) has
changed significantly over the past two decades with the development of numerous systemic …
changed significantly over the past two decades with the development of numerous systemic …
Treatment burden of Medicare beneficiaries with stage I non–small-cell lung cancer
Purpose: To quantify the burden and complexity associated with treatment of Medicare
beneficiaries with stage I non–small-cell lung cancer (NSCLC). Methods: Using the SEER …
beneficiaries with stage I non–small-cell lung cancer (NSCLC). Methods: Using the SEER …